Redeye takes a neutral stance towards the Cellavision share before the Q3 report on October 23. We expect to continue to see a significant negative impact from the corona crisis on both sales and EBIT. We still have a positive long-term view, even with the corona headwind and the departure of the CEO and SO. The share volatility has been significant during the year and is currently trading above our base case of SEK 325 per share.